The article from the Media Office of Abu Dhabi discusses the Personalised Precision Medicine Programme for Oncology, launched by the Department of Health – Abu Dhabi (DoH). This innovative initiative is making significant strides in providing tailored care to cancer patients in the region.
The Personalised Precision Medicine Programme for Oncology was launched in October 2022, marking the region’s first such initiative. It is a collaborative effort involving the DoH, Cleveland Clinic Abu Dhabi, G42 Healthcare, and other strategic partners.
So far, the programme has provided tailored treatment plans to over 256 Emirati cancer patients in Abu Dhabi. It comprises personalised treatment and prevention plans developed by genetic counsellors and specialists.
Eligible patients underwent screening for 47 genes to enhance their clinical care. This genetic screening assists in identifying specific mutations linked to cancers, significantly improving treatment efficiency and patient recovery.
This programme also extends its reach by including preventive plans for the families of patients who tested positive for inherited gene mutations. Specifically, tailored preventive plans were implemented for 207 family members to help mitigate their cancer risk.
Overall, 200 patients aged between 25 and 50 years, selected from the Emirati Genome Programme (EGP), were tested for gene variants associated with higher risks of breast, ovarian, colorectal, and lung cancers. Those identified as high-risk received personalised prevention plans and referrals to specialised clinics for monitoring and intervention.
The programme aims to extend beyond oncology and tackle other chronic diseases in the future. The DoH plans to consolidate learnings, unify efforts, and apply innovation and research to advance precision medicine outcomes for various health conditions.
The Personalised Precision Medicine Programme for Oncology leverages cutting-edge technologies, including genomic technologies and artificial intelligence, to make gene discoveries, understand molecular pathways, and identify new targets for biomarkers and therapies. This approach aligns with international standards and best practices.
The DoH has developed regulatory policies and clinical testing guidelines in collaboration with Cleveland Clinic Abu Dhabi. These guidelines are designed to enhance diagnosis, treatment, and prevention strategies, especially for breast and ovarian cancer-associated genes.
Overall, the programme has significantly enhanced treatment efficacy, reduced adverse effects, and provided valuable prognostic insights. It has also helped position Abu Dhabi as a prominent destination for life sciences and innovation in healthcare.
In conclusion, the Personalised Precision Medicine Programme for Oncology in Abu Dhabi represents a transformative advancement in healthcare, focusing on individualized care through genetic profiling, advanced technologies, and collaborative research efforts.
🌍 *Could a twice-yearly shot revolutionize HIV prevention?*
Gilead Sciences has submitted key applications to the EMA for lenacapavir, a groundbreaking HIV-1 capsid inhibitor designed for use as pre-exposure prophylaxis (PrEP). With promising trial results indicating a significant reduction in HIV infections, this innovation could enhance adherence to prevention strategies globally. Discover more about this game-changing development!
#SyenzaNews #globalhealth #healthcareInnovation
🌍 Can collaboration redefine Africa’s health landscape?
A newly signed Memorandum of Understanding between Africa CDC and Global Health EDCTP3 promises to enhance health research, clinical trials, and pandemic preparedness on the continent. With a focus on training, local manufacturing, and equitable partnerships, this initiative aims to address pressing global health challenges while improving health outcomes across Africa.
Look into the details of this transformative partnership and its implications for the future of healthcare in the region!
#SyenzaNews #globalhealth #HealthcareInnovation
🚨 Are we doing enough to tackle the imminent breast cancer crisis in Africa?
A recent WHO report reveals alarming trends, predicting that 135,000 women could succumb to breast cancer by 2040 unless urgent actions are taken. The report highlights critical gaps in healthcare infrastructure and capacity, emphasizing the need for investment in screening programs and professional training to improve outcomes across the continent.
Review the full article to explore the necessary steps towards reinforcing breast cancer control measures in Africa.
#SyenzaNews #globalhealth #oncology #HealthTech
SPEAK WITH US
CORRESPONDENCE ADDRESS
1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA
WRITE US
JOIN NEWSLETTER
